Share Twitter LinkedIn Facebook Email Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the design of the TOURMALINE-MM4 study and answers if the trail met its primary endpoint.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read
